Your browser doesn't support javascript.
loading
OCaR1 endows exocytic vesicles with autoregulatory competence by preventing uncontrolled Ca2+ release, exocytosis, and pancreatic tissue damage.
Tsvilovskyy, Volodymyr; Ottenheijm, Roger; Kriebs, Ulrich; Schütz, Aline; Diakopoulos, Kalliope Nina; Jha, Archana; Bildl, Wolfgang; Wirth, Angela; Böck, Julia; Jaslan, Dawid; Ferro, Irene; Taberner, Francisco J; Kalinina, Olga; Hildebrand, Staffan; Wissenbach, Ulrich; Weissgerber, Petra; Vogt, Dominik; Eberhagen, Carola; Mannebach, Stefanie; Berlin, Michael; Kuryshev, Vladimir; Schumacher, Dagmar; Philippaert, Koenraad; Camacho-Londoño, Juan E; Mathar, Ilka; Dieterich, Christoph; Klugbauer, Norbert; Biel, Martin; Wahl-Schott, Christian; Lipp, Peter; Flockerzi, Veit; Zischka, Hans; Algül, Hana; Lechner, Stefan G; Lesina, Marina; Grimm, Christian; Fakler, Bernd; Schulte, Uwe; Muallem, Shmuel; Freichel, Marc.
Afiliação
  • Tsvilovskyy V; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Ottenheijm R; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.
  • Kriebs U; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Schütz A; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.
  • Diakopoulos KN; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Jha A; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Bildl W; Comprehensive Cancer Center München, Chair for Tumor Metabolism, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich, Bavaria, Germany
  • Wirth A; Epithelial Signaling and Transport Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, USA.
  • Böck J; Institute for Physiology, University of Freiburg, Freiburg, Germany.
  • Jaslan D; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Ferro I; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.
  • Taberner FJ; Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Kalinina O; Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Hildebrand S; Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Wissenbach U; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Weissgerber P; Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas, Sant Joan d'Alacant, Spain.
  • Vogt D; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarbrücken, Germany.
  • Eberhagen C; Institut für Pharmakologie und Toxikologie, Universität Bonn, Bonn, Germany.
  • Mannebach S; Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany.
  • Berlin M; Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany.
  • Kuryshev V; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Schumacher D; Institute of Molecular Toxicology and Pharmacology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
  • Philippaert K; Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany.
  • Camacho-Londoño JE; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Mathar I; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.
  • Dieterich C; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Klugbauer N; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Biel M; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Wahl-Schott C; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.
  • Lipp P; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Flockerzi V; Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
  • Zischka H; University Hospital Heidelberg, Department of Medicine III: Cardiology, Angiology and Pneumology, Heidelberg, Germany.
  • Algül H; Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Fakultät für Medizin, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
  • Lechner SG; Center for Integrated Protein Science Munich (CIPS-M) and Center for Drug Research, Department of Pharmacy, Ludwig-Maximilians-Universität München, and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
  • Lesina M; Walter Brendel Centre of Experimental Medicine, Biomedical Center, Institute of Cardiovascular Physiology and Pathophysiology, Medical Faculty, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
  • Grimm C; Institute for Molecular Cell Biology, Center for Molecular Signaling (PZMS), Universität des Saarlandes, Homburg, Germany.
  • Fakler B; Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany.
  • Schulte U; Institute of Molecular Toxicology and Pharmacology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
  • Muallem S; Institute of Toxicology and Environmental Hygiene, Technical University Munich, School of Medicine, Munich, Germany.
  • Freichel M; Comprehensive Cancer Center München, Chair for Tumor Metabolism, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich, Bavaria, Germany
J Clin Invest ; 134(7)2024 04 01.
Article em En | MEDLINE | ID: mdl-38557489
ABSTRACT
Regulated exocytosis is initiated by increased Ca2+ concentrations in close spatial proximity to secretory granules, which is effectively prevented when the cell is at rest. Here we showed that exocytosis of zymogen granules in acinar cells was driven by Ca2+ directly released from acidic Ca2+ stores including secretory granules through NAADP-activated two-pore channels (TPCs). We identified OCaR1 (encoded by Tmem63a) as an organellar Ca2+ regulator protein integral to the membrane of secretory granules that controlled Ca2+ release via inhibition of TPC1 and TPC2 currents. Deletion of OCaR1 led to extensive Ca2+ release from NAADP-responsive granules under basal conditions as well as upon stimulation of GPCR receptors. Moreover, OCaR1 deletion exacerbated the disease phenotype in murine models of severe and chronic pancreatitis. Our findings showed OCaR1 as a gatekeeper of Ca2+ release that endows NAADP-sensitive secretory granules with an autoregulatory mechanism preventing uncontrolled exocytosis and pancreatic tissue damage.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canais de Cálcio / Cálcio Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canais de Cálcio / Cálcio Idioma: En Ano de publicação: 2024 Tipo de documento: Article